Winder, Alec A.
Boyer, Zoe
Ch’ng, Sydney
Stretch, Jonathan R.
Saw, Robyn P. M.
Shannon, Kerwin F.
Pennington, Thomas E.
Nieweg, Omgo E.
Varey, Alexander H. R.
Scolyer, Richard A.
Thompson, John F.
Cust, Anne E.
Lo, Serigne N.
Spillane, Andrew J.
Smith, Andrea L.
Funding for this research was provided by:
The Cameron Family Foundation
National Health and Medical Research Council (1093017, 2008454, 2018514)
Melanoma Centre of Research Excellence (1135285)
University of Sydney
Article History
Received: 15 August 2023
Accepted: 28 April 2024
First Online: 27 May 2024
Disclosure
: Richard A. Scolyer has received fees for professional services from MetaOptima Technology Inc., F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, and GlaxoSmithKline. Robyn P.M. Saw has received honoraria for advisory board participation from MSD, Novartis and Qbiotics, and speaking honoraria from BMS and Novartis. Andrew J. Spillane has received an honoraria from Eli Lily Australia. John F. Thompson has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Inc, and travel and conference support from GSK, Provectus Inc. and Novartis. Alexander H.R. Varey has received an honorarium from Novartis. Serigne N. Lo has received a stipend for editorial services at the British Journal of Dermatology. Alec A. Winder, Zoe Boyer, Sydney Ch’ng, Jonathan R. Stretch, Kerwin F. Shannon, Thomas E. Pennington, Omgo E. Nieweg, Anne E. Cust, and Andrea L. Smith have no disclosures to declare in relation to this manuscript.